910553-12-7

Basic information

• Product Name: 2-Methylthiophene-3-boronic acid pinacol ester
• Synonyms: 2-Methylthiophene-3-boronic acid pinacol ester;4,4,5,5-tetramethyl-2-(2-methylthiophen-3-yl)-1,3,2-dioxaborolane;4,4,5,5-TetraMethyl-2-(2-Methyl-3-thienyl)-1,3,2-dioxaborolane;4,4,5,5-Tetramethyl-2-(2-methylthiophen-3-yl)
• CAS NO: 910553-12-7
• Molecular Formula: C11H17BO2S
• Molecular Weight: 224.13
• Mol File: 910553-12-7.mol

Chemical Properties

• Boiling Point: 303.9 °C at 760 mmHg
• Flash Point: 137.6 °C
• Appearance: /
• Density: 1.06g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Methylthiophene-3-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methylthiophene-3-boronic acid pinacol ester(910553-12-7)
• EPA Substance Registry System: 2-Methylthiophene-3-boronic acid pinacol ester(910553-12-7)

Safety Data

• Hazardous Substances Data: 910553-12-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Methylthiophene-3-boronic acid pinacol ester is used as a building block for the synthesis of new molecules with potential therapeutic applications. Its unique reactivity and structure allow for the development of innovative drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Methylthiophene-3-boronic acid pinacol ester is employed as a key intermediate in the synthesis of novel agrochemicals. Its ability to form carbon-carbon bonds through Suzuki-Miyaura cross-coupling reactions enables the creation of molecules with potential agricultural applications, such as new pesticides or herbicides.
Used in Organic Synthesis:
2-Methylthiophene-3-boronic acid pinacol ester is utilized as a versatile reagent in organic synthesis. Its participation in Suzuki-Miyaura cross-coupling reactions allows chemists to efficiently construct complex organic molecules with diverse functional groups and structural motifs, facilitating the discovery of new compounds with various applications in materials science, pharmaceuticals, and agrochemicals.

Upstream product

• 30319-05-2 3-bromo-2-methylthiophene 
• 73183-34-3 bis(pinacol)diborane 
• 554-14-3 2-Methylthiophene 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 

Downstream Products

• 177735-10-3 (2-methylthiophen-3-yl)boronic acid 

Relevant articles and documents

Reversible Photoswitching between Fluorescence and Room Temperature Phosphorescence by Manipulating Excited State Dynamics in Molecular Aggregates

Regulation of fluorescence–phosphorescence pathways in organic molecular aggregate remains a challenge due to the complicated singlet–triplet excited state dynamics process. Herein, we demonstrated a successful example (o-BFT) to realize photoreversible fluorescence and room temperature phosphorescence (RTP) switching based on an effective strategy of integrating a phosphor (dibenzofuran) with a photoswitch (dithienylbenzothiophene). o-BFT exhibited dual emission of fluorescence and RTP in both powder and doping polymer film. Notably, the long-lived RTP of o-BFT could be repeatedly erased and restored through reversible photocyclization and decyclization under alternate ultraviolet and visible photoirradiation. In-depth theoretical and spectroscopic investigations revealed that the triplet inactivation was dominated by a photo-controlled triplet-to-singlet F?rster resonance energy transfer from light-activated o-BFT to photoisomer c-BFT. Yet, the initial fluorescence could be preserved in this process to afford a photoreversible fluorescence-RTP switching.

Remarkably Efficient Iridium Catalysts for Directed C(sp2)-H and C(sp3)-H Borylation of Diverse Classes of Substrates

Here we describe the discovery of a new class of C-H borylation catalysts and their use for regioselective C-H borylation of aromatic, heteroaromatic, and aliphatic systems. The new catalysts have Ir-C(thienyl) or Ir-C(furyl) anionic ligands instead of the diamine-type neutral chelating ligands used in the standard C-H borylation conditions. It is reported that the employment of these newly discovered catalysts show excellent reactivity and ortho-selectivity for diverse classes of aromatic substrates with high isolated yields. Moreover, the catalysts proved to be efficient for a wide number of aliphatic substrates for selective C(sp3)-H bond borylations. Heterocyclic molecules are selectively borylated using the inherently elevated reactivity of the C-H bonds. A number of late-stage C-H functionalization have been described using the same catalysts. Furthermore, we show that one of the catalysts could be used even in open air for the C(sp2)-H and C(sp3)-H borylations enabling the method more general. Preliminary mechanistic studies suggest that the active catalytic intermediate is the Ir(bis)boryl complex, and the attached ligand acts as bidentate ligand. Collectively, this study underlines the discovery of new class of C-H borylation catalysts that should find wide application in the context of C-H functionalization chemistry.

Efficient Rh-catalyzed C-H borylation of arene derivatives under photochemical conditions

Photocatalysis allows innovations in organic synthesis. Among the various catalytic reactions, CH-functionalizations offer valuable possibilities for the refinement of easily available building blocks. In this respect, catalytic borylation is of interest, too. So far, most of the catalytic borylation reactions are performed under thermal conditions at comparably high temperatures. Here, we describe a new synthetic route for efficient borylation reactions of arenes using a photocatalytic pathway. This novel approach allows the synthesis of a broad variety of borylated arenes and heteroarenes under mild conditions. Applying trans-[Rh(PMe3)2(CO)Cl] as an active photocatalyst and HBPin as an boron source, we achieved high TON. A catalytic cycle that relies on a Rh(i)-Rh(iii) interconversion is proposed.

Harnessing C-H Borylation/Deborylation for Selective Deuteration, Synthesis of Boronate Esters, and Late Stage Functionalization

Ir-catalyzed deborylation can be used to selectively deuterate aromatic and heteroaromatic substrates. Combined with the selectivities of Ir-catalyzed C-H borylations, uniquely labeled compounds can be prepared. In addition, diborylation/deborylation reactions provide monoborylated regioisomers that complement those prepared by C-H borylation. Comparisons between Ir-catalyzed deborylations and Pd-catalyzed deborylations of diborylated indoles described by Movassaghi are made. The Ir-catalyzed process is more effective for deborylating aromatics and is generally more effective in the monodeborylation of diborylated thiophenes. These processes can be applied to complex molecules such as clopidogrel.

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

METHOD OF INHIBITING FLT3 KINASE

A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula (I): wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.